Avastin scintigraphy in surveillance of bevacizumab treatment in a patient with neurofibromatosis type 2: a case report.

Abstract

A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.

• Authors: Michelle W J Versleijen, Berit M Verbist, Jef J S Mulder, Lioe-Fee de Geus-Oei, Carla M L van Herpen
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 39 Issue 3 Pg. 277-80 (Mar 2014) ISSN: 1536-0229 [Electronic] United States
• PMID: 24445270 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Neurofibromatosis 2 (diagnostic imaging, drug therapy)
• Neuroma, Acoustic (diagnostic imaging, drug therapy)
• Radionuclide Imaging